Superluminal Medicines
MA - BostonBiotechnology
Focus: Superluminal Medicines is a Boston-based biotechnology company focused on discovering and developing GPCR-targeting small molecules for neurological indications. The company operates as a pre-revenue biotech with a lean, specialized pipeline focused on a validated druggable target class.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Open Jobs
7-2 this month
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Should You Work at Superluminal Medicines?
AI assessmentSuperluminal offers a focused scientific opportunity in a validated modality, but the absence of pipeline visibility, financial disclosure, and small team size present material career and stability risks best suited for scientists seeking early-stage ownership rather than traditional advancement.
Why Work Here
- Specialized focus on GPCR biology—a validated, historically productive target class with multiple marketed drugs—offers deep scientific expertise building
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Superluminal Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.